PL351492A1 - Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them - Google Patents

Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Info

Publication number
PL351492A1
PL351492A1 PL00351492A PL35149200A PL351492A1 PL 351492 A1 PL351492 A1 PL 351492A1 PL 00351492 A PL00351492 A PL 00351492A PL 35149200 A PL35149200 A PL 35149200A PL 351492 A1 PL351492 A1 PL 351492A1
Authority
PL
Poland
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
polymorphic forms
antidiabetic agent
Prior art date
Application number
PL00351492A
Other languages
English (en)
Inventor
Om Reddy Gaddam
Rajender Kumar Potlapally
Raju Sirisilla
Vyas Krishnamurthi
Sreenivasa Rao Dharmaraja
Ramabhadra Sarma Mamillapalli
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of PL351492A1 publication Critical patent/PL351492A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PL00351492A 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them PL351492A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (en) 1999-04-16 1999-04-16 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
IN436MA1999 1999-04-19

Publications (1)

Publication Number Publication Date
PL351492A1 true PL351492A1 (en) 2003-04-22

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00351492A PL351492A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Country Status (17)

Country Link
EP (1) EP1171430A1 (xx)
CN (1) CN1351597A (xx)
AU (1) AU3831300A (xx)
BG (1) BG106022A (xx)
BR (1) BR0010683A (xx)
CA (1) CA2370401A1 (xx)
CZ (1) CZ20013711A3 (xx)
EE (1) EE200100529A (xx)
HR (1) HRP20010748A2 (xx)
HU (1) HUP0200758A3 (xx)
IL (1) IL145958A0 (xx)
MX (1) MXPA01010472A (xx)
NO (1) NO20015016L (xx)
PL (1) PL351492A1 (xx)
RU (1) RU2001130883A (xx)
TR (1) TR200103851T2 (xx)
WO (1) WO2000063192A1 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309818T1 (de) 2000-03-08 2005-12-15 Novo Nordisk As Senkung des serum cholesterols
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
IL162620A0 (en) 2001-12-21 2005-11-20 Novo Nordisk As Amide derivatives as gk activators
SI1505066T1 (sl) * 2002-04-19 2007-04-30 Faes Farma Sa Polimorf 4-(2-(4-(1-(2-etoksietil)-1h-benzimidazol-2-il) -1-piperidinil)-alfa, alfa-dimetil-benzenocetne kisline
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
JP2007503453A (ja) 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ 肥満症を治療するための新規化合物
BRPI0414890A (pt) 2003-09-30 2006-12-12 Novo Nordisk As composto, métodos de retardar a progressão de igt para diabete tipo 2, e de diabete tipo 2 para diabete que requer insulina, de tratar a obesidade ou prevenir o excesso de peso, de regular o apetite, de induzir saciedade, de impedir o ganho de peso, de aumentar o gasto de energia, e de tratar uma doença ou estado, composição farmacêutica, e, uso de um composto
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
MX2007006420A (es) 2004-12-03 2007-07-19 Novo Nordisk As Activadores heteroaromaticos de glucocinasa.
BRPI0613564A2 (pt) 2005-07-04 2011-01-18 Novo Nordisk As compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
SI1951658T1 (sl) 2005-11-17 2012-11-30 Lilly Co Eli Antagonisti glukagonskega receptorja priprava interapevtska uporaba
SG170785A1 (en) 2006-03-28 2011-05-30 Transtech Pharma Benzothiazoles having histamine h3 receptor activity
AU2007267197B2 (en) 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
EP2097388B1 (en) 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
EP2086951B1 (en) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
CA2792663A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
CA2830974A1 (en) 2011-03-28 2012-10-04 Jesper F. Lau Novel glucagon analogues
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
MA49883A (fr) 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (xx) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (fr) * 1996-03-13 1998-04-30 Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
EP0844997A1 (en) * 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU1887999A (en) * 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EE200100529A (et) 2002-12-16
CA2370401A1 (en) 2000-10-26
NO20015016L (no) 2001-12-11
EP1171430A1 (en) 2002-01-16
TR200103851T2 (tr) 2002-04-22
HRP20010748A2 (en) 2003-02-28
MXPA01010472A (es) 2002-05-06
BG106022A (bg) 2002-04-30
BR0010683A (pt) 2003-07-01
HUP0200758A3 (en) 2003-07-28
CZ20013711A3 (cs) 2002-07-17
RU2001130883A (ru) 2004-03-20
IL145958A0 (en) 2002-07-25
HUP0200758A2 (hu) 2002-07-29
CN1351597A (zh) 2002-05-29
NO20015016D0 (no) 2001-10-15
AU3831300A (en) 2000-11-02
WO2000063192A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
HUP0200758A3 (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
AU4465200A (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
AU2953699A (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
HUP0203559A3 (en) Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them
HUP0203257A3 (en) Polymorphic forms of atorvastatin calcium, process for their preparations and pharmaceutical compositions containing them
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
IL149618A0 (en) Pharmaceutical compositions comprising thiazolidinedione and process for preparation thereof
HUP0203183A3 (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use
HUP0003844A3 (en) Novel spiroazabicyclic heterocyclic compounds, process for their preparation, their use and pharmaceutical compositions containing them
HUP0400998A3 (en) Novel compounds of anti-inflammatory, immunomodulatory and anti-proliferatory effect, process for their preparation and pharmaceutical compositions containing them
PL355844A1 (en) Novel pharmaceutical compositions of anti-tubrcular drugs and process for their preparation
HUP0105108A3 (en) Amide compounds, process for their preparation and pharmaceutical compositions containing them
AP2001002183A0 (en) Ethanolate of zithromycin process for manufacture and pharmaceutical compositions thereof
HUP0100731A3 (en) New oxazolidine-, thiazolidine-, pyrrolidine-and piperidin derivatives process for their preparation and pharmaceutical compositions containing them
HUP0104762A3 (en) Pharmaceutical moxifloxacin compositions and process for their preparation
HUP0200881A3 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0105160A3 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-betha-cyclodextrin or 2-hydroxypropyl-betha-cyclodextrin and method for its preparation and pharmaceutical compositions containing them
HUP0202654A3 (en) Pharmaceutical compositions of fibrinolytic agent and process for preparation thereof
HUP0200580A3 (en) Polymorphic crystalline forms of celecoxib, process their preparation and pharmaceutical compositions containing them
HUP0204318A3 (en) Torsemide polymorphic forms, process for their preparation, pharmaceutical compositions containing them and their use
HUP0401163A3 (en) L crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation and pharmaceutical compositions containing the crystalline forms
AP2001002355A0 (en) Derivatives of purine their preparation process and pharmaceutical compositions containing them
HUP0003053A3 (en) Crystalline forms of 33-epichloro-33-desoxyascomycin, process for their preparation and pharmaceutical compositions containing them
EG22344A (en) Process for preparing of novel pharmaceutical composition
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)